Pfizer
MD, Vice President Global Medical Lead Respiratory Vaccines
Bradford Gessner is a pediatrician and medical epidemiologist who completed his undergraduate training at Dartmouth College, medical school at the University of Florida, pediatric residency at the University of Colorado, preventive medicine residency and Masters of Public Health at the University of Washington, and Epidemic Intelligence Service fellowship with the US CDC. He started a maternal-child health epidemiology unit at the Alaska Division of Public Health that grew from one person to 15 and eventually won the National MCH Epidemiology Award. For 20 years, he served as the Scientific Director and Chief Scientific Officer with Agence de Medicine Preventive, based in Paris, France and Abidjan, Cote d’lvoire. In this role he initiated field studies primarily in impoverished settings and for most vaccine-preventable etiologies; study types included large RCTs, immunogenicity, surveillance, carriage, vaccine effectiveness, anthropology, logistics, economics, and implementation research. During this time, he served on numerous WHO expert working groups, several SAGE working groups, WHO’s IVIR-AC and IPAC committees, and the Gavi Board of Directors as the Research and Technical Health Institutions representative. From 2016 to 2019 he worked with Pfizer as the Global Medical Director for Pneumococcal Vaccines, adding Lyme Vaccine in 2020. Since 2021 has served as the Global Medical Lead for Respiratory Vaccines overseeing all post-licensure scientific work and medical affairs for Pfizer’s pneumococcal, RSV, and GBS vaccines. He is the author of approximately 280 peer-reviewed manuscripts from 40 countries, primarily in the field of vaccines and vaccine-preventable diseases with a focus on study design and assessing the public health value of vaccines.

Moderator of 1 Session

Session Type
Industry Sponsored Symposium
Date
Tue, 22.02.2022
Session Time
04:30 PM - 06:00 PM
Room
Sala A
Session Description
Over 20 Years of Pneumococcal Conjugate Vaccine Use: Clinical and Public Health Benefits to Infants and Children - Symposium Supported by PfizerSession Description: Listen in as experts review the current state of pneumococcal disease:•Impact of PCVs over 20 years of use•Epidemiology and antimicrobial resistance of pneumococcal disease in Latin America•Importance of serotype 19A

Presenter of 2 Presentations

Welcome and introduction

Session Type
Industry Sponsored Symposium
Date
Tue, 22.02.2022
Session Time
04:30 PM - 06:00 PM
Room
Sala A
Lecture Time
04:30 PM - 04:35 PM

Q&A

Session Type
Industry Sponsored Symposium
Date
Tue, 22.02.2022
Session Time
04:30 PM - 06:00 PM
Room
Sala A
Lecture Time
05:40 PM - 06:00 PM